

# 20. Arbeitstagung „Experimentelle Neuroonkologie“

29. April und 30. April 2011

## PROGRAMM

### Freitag, 29. April 2011

**12.30 - 13.30 Uhr: Ankunft, Registrierung, Imbiss**

**13.30 Uhr: Begrüßung und Eröffnung**  
Erdlenbruch

**13.40 - 15.20 Uhr: Experimentelle Neuroonkologie Teil I (4)**  
Vorsitz: O. Witt / NN

- C. D. Kühnöl, C. Würfel, M. S. Staeger, C. M. Kramm  
*„Genes involved in epithelial-mesenchymal transition in carcinomas may also play a role in migration and invasion of human glioblastoma cells“*
- Sebastian Bender<sup>1,2</sup>, Hendrik Witt<sup>1,2</sup>, Till Milde<sup>2,3</sup>, Marina Ryzhova<sup>4</sup>, Andreas E. Kulozik<sup>2</sup>, Olaf Witt<sup>2,3</sup>, Peter Lichter<sup>1</sup>, Andrey Korshunov<sup>5</sup>, Stefan M. Pfister<sup>1,2</sup>  
*„Molecular outcome prediction in intracranial ependymoma based on WDR16 expression status“*
- Hendrik Witt<sup>1,2</sup>, Stephen C. Mack<sup>3,4</sup>, Marina Ryzhova<sup>5</sup>, Sebastian Bender<sup>1,2</sup>, Martin Sill<sup>6</sup>, Ruth Isserlin<sup>7</sup>, Axel Benner<sup>6</sup>, et.al., Stefan M. Pfister<sup>1,2</sup>  
*“Identification of two molecular and clinical distinct entities of posterior fossa Ependymoma“*
- J. Lacroix<sup>1,2</sup>, F. Schlund<sup>1</sup>, K. Adolph<sup>1</sup>, B. Leuchs<sup>1</sup>, T. Hielscher<sup>3</sup>, J.R. Schlehofer<sup>1</sup>, J. Rommelaere<sup>1</sup>, S. M. Pfister<sup>2,4</sup>, O. Witt<sup>2,5</sup> and H. Witt<sup>4</sup>  
*“Identification of target genes of Parvovirus H-1 (H-1PV) induced cytopathic effects in medulloblastoma“*

**15.20 - 15.45 Uhr: Kaffeepause**

**15.45 - 17.00 Uhr: key note lecture**

**PD Dr. Alexandre Arcaro**

**“Targeting the PI3K/Akt/mTOR pathway in childhood brain tumors“**

**Department für klinische Forschung, Medizinische Fakultät, University of Bern, Switzerland**

**17.00 - 17.20 Uhr: Kaffeepause**

**17.20 - 19.00 Uhr: Experimentelle Neuroonkologie Teil II (4)**

Vorsitz: S. Fulda / NN

- M Kool<sup>1,2</sup>, J Koster<sup>2</sup>, M. Remke<sup>1</sup>, A Korshunov<sup>1</sup>, T Hielscher<sup>1</sup>, H Witt<sup>1</sup>, P Northcott<sup>1,3</sup>, A Schouten-van Meeteren<sup>2</sup>, et.al. , S Pfister<sup>1</sup>  
*“Molecular subtypes in medulloblastoma: An international metaanalysis profiles, genetic aberrations, clinicopathological features and survival”*
- David TW Jones<sup>1</sup>, Marc Zapatka<sup>1</sup>, Natalie Jäger<sup>2</sup>, Qi Wang<sup>2</sup>, Adrian Stuetz<sup>3</sup>, Tobias Rausch<sup>3</sup>, et. al. , Stefan Pfister<sup>1,8</sup>  
*“First results from the international cancer genome consortium PedBrain Tumor Project on Whole-Genome Deep Sequencing in Medulloblastoma”*
- Hendrik Witt<sup>1,2</sup>, David TW Jones<sup>1</sup>, Marc Zapatka<sup>1</sup>, Huriye Cin<sup>1</sup>, Marina Ryzhova<sup>4</sup>, Marc Remke<sup>1,2</sup>, Andreas E Kulozik<sup>2</sup>, Olaf Witt<sup>2,3</sup>, Peter Lichter<sup>1</sup>, Andrey Korshunov<sup>5</sup> and Stefan M Pfister<sup>1,2</sup>  
*“Identification of a CpG Island Methylator Phenotype (PA-CIMP) in a Subgroup of Pilocytic Astrocytoma”*
- Huriye Cin<sup>1</sup>, Claus Meyer<sup>2</sup>, Ricarda Herr<sup>3</sup>, Wibke G. Janzarik<sup>4,5</sup>, Sally Lambert<sup>6</sup>, David T.W. Jones<sup>1</sup> et al. , Stefan Pfister<sup>1,9</sup>  
*“FAM131B-BRAF fusion gene resulting from 7q34 deletion leads to MAPK pathway activation in pilocytic astrocytoma”*

**19.30 Uhr: Abendessen**

**Gemeinsame Gesprächsrunde**

**anschl. für Interessierte  
ca. 22:00 Uhr:**

**Führung: „Geschichte der Stadt Minden  
und ihre Bauwerke“**

**Samstag, 30. April 2011**

**08.30 – 9.45 Uhr: Experimentelle Neuroonkologie Teil III (3)**

Vorsitz: G. Fleischhack / NN

- Till Milde<sup>1</sup>, Manuela Zucknick<sup>3</sup>, Mathias Koch<sup>1</sup>, Andrey Korshunov<sup>4,5</sup>, Hendrik Witt<sup>2,6</sup>, Marc Remke<sup>2,6</sup>, Manfred Jugold<sup>7</sup>, Andreas von Deimling<sup>4,5</sup>, Andreas E. Kulozik<sup>2</sup>, Axel Brenner<sup>3</sup>, Stefan Pfister<sup>2,6</sup>, Olaf Witt<sup>1,2</sup>  
*“The pediatric brain tumor preclinical testing program: evaluation of an individualized molecular treatment approach”*
- R. Unland<sup>1</sup>, S. Schlosser<sup>1</sup>, J. Mühlisch<sup>1</sup>, M.C. Frühwald<sup>1</sup>  
*“Epigenetic deregulation of the dopamine receptor D4 in pediatric brain tumors”*
- Christina Mullins<sup>1</sup>, Michael Linnebacher<sup>2</sup>, Björn Schneider<sup>3</sup>, Florian Stockhammer<sup>4</sup>, Carl Friedrich Classen<sup>1</sup>  
*“Establishment and characterization of primary GBM cell lines”*

**09.45 - 10.05 Uhr: Kaffeepause**

**10.05 – 11.20 Uhr: Experimentelle Neuroonkologie Teil III (3)**

Vorsitz: S. Pfister / NN

- P. Duenisch<sup>1</sup>, S. Grube<sup>1</sup>, R. Kalff<sup>1</sup>, R. Bauer<sup>2</sup>, C. Ewald<sup>1</sup>  
*“Fatty acid synthase (FAS-272) expression increases with rise of WHO-grade and serves as indicator for the malignant transformation in human gliomas”*
- Thomas Unterkircher, Silvia Cristofanon, Simone Fulda  
*“Bortezomib primes glioblastoma including glioblastoma stem cells for TRAIL by increasing tBid stability and mitochondrial apoptosis”*
- Julia Bode<sup>1</sup>, Adi Sabag<sup>2</sup>, Silke Kietz<sup>1</sup>, Gera Neufeld<sup>2</sup>, Max Lakomek<sup>1</sup>  
*“Effects of class-3 semaphorins on brain tumour progression”*

**11.20 - 11.40 Uhr: Kaffeepause**

**11.40 – 12.55 Uhr: Experimentelle Neuroonkologie Teil III (3)**

Vorsitz: B. Erdlenbruch / NN

- Christoph Dohm, Petra Hülper, Pawel Kermer, Herwig Strik, Jochen Weishaupt  
*“cdk-inhibition as putative new glioblastoma therapy”*

- Lien Vandenberk, Tina Verschuere, Kevin Vanhoven, Carolien KDks, Steven De Vleeschouwer, Stefaan W. Van Gool  
*“Immunotherapy for malignant glioma: preclinical models to improve efficacy of the immune attack”*
- Carolien Koks, Steven De Vleeschouwer, Hilko Ardon, Stefaan W. Van Gool  
*“Immunotherapy for malignant glioma: current results of the clinical trials”*

**12.55 - 13.10 Uhr: Abschlussdiskussion und Planung der 21. Arbeitstagung Experimentelle Neuroonkologie**

**Ca. 13.10 Uhr: Ende der Veranstaltung  
anschließend Imbiss**

Mit freundlicher Unterstützung der:

Deutschen Kinderkrebsstiftung



und der Firmen:

Biotest AG

MSD / Essex Pharma GmbH

mundipharma